Friday, April 17, 2015 Last update: 9:33 PM - Covering Large & Obscure Tech Companies Since 1996

New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO 2014

Companies mentioned in this article: Corcept Therapeutics

CHICAGO, IL -- (Marketwired) -- 06/19/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept's multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing's syndrome who have glucose intolerance and have failed or cannot have surgery.

"Cushing's syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients' lives. The disease often significantly affects patients' metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Because Cushing's syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years."

Cushing's syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing's syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:

Date         Session Time Title                     Authors
Saturday,    11:30am-     Late-Night Salivary       Ty Brian Carroll, MD;
 June 21,    1:00pm       Cortisol for the          Bradley R Javorsky, MD;
 2014                     Diagnosis of Recurrent    James W Findling, MD
                          Cushing's Disease:
                          Evidence of Clinical
                          Benefit from Early
                          Clinical Management in a  Elizabeth E King, MD;
                          Female with Persistent    Simone M Howell, RN,
                          Cushing's Disease         CCRA
                          Treated with
                          Mifepristone for Four
             1:00-3:00pm  Effect of Mifepristone    Vijay Babu Balakrishnan;
                          on Cushing's syndrome     Pankaj Sharda, MBBS, MD;
                          Secondary to Bilateral    Elias Said Siraj, MD
                          Adrenal Adenomas: A Case
Sunday, June 1:00-3:00pm  Mifepristone for          Audrey Elisabeth
 22, 2014                 Refractory Cushing's      Arzamendi, MD; Alison
                          Syndrome in a Patient     Marie Semrad, DO
                          with CKD Hyperkalemia
                          Undergoing Surgical
                          Exodontia and Weight
                          Loss: Recommendations
                          for Clinical/Biochemical
                          Monitoring and
                          Perioperative Dosing
Monday, June 1:00-3:00pm  A Case Report of a 37     Howard A Brand, MD;
 23, 2014                 y/o Woman Diagnosed with  Kimberly Calcagno, MA;
                          Cushing's Disease         Michele Lamerson, RN,
                          Presenting As Pituitary   MS, CPNP
                          Apoplexy after Multiple
                          Treatment Failures
                          Effectively Responds to
                          Discontinuation of        Kevin C.J. Yuen, MD,
                          Insulin, Oral             FRCP (UK); Harold I
                          Antidiabetic and          Magazine, PhD
                          Medications in a Patient
                          with Cushing's Disease
                          Following Mifepristone
                          (MIFE) Therapy
                          Persistent Weight Loss    Henry G. Fein, MD; T.
                          in Patients Treated with  Brooks Vaughan III, MD;
                          Mifepristone (MIFE) for   Coleman Gross; Dat
                          Cushing's Syndrome:       Nguyen
                          Results from the Seismic
                          & Long Term Extension
                          Improved Activities of    Daphne T Adelman, BSN,
                          Daily Living, Normal      MBA; Simone M Howell,
                          Mood and Quality of       RN, CCRA
                          Life: 4 Years of
                          Treatment Data in a
                          Premenopausal Woman with
                          Cushing's Disease

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company's first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.


Investor Contact
Charles Robb
Corcept Therapeutics Incorporated
Chief Financial Officer
Email Contact

Media Contact
Brian Baxter for Corcept
Lazar Partners Ltd.
Email Contact